You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

476 Results
Drug
Other Name(s): Rituxan® , Truxima™ , Riximyo™ , Ruxience™ , Riabni™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2025
Drug
Other Name(s): Firmagon®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Feb 2025
Drug
Other Name(s): Cosmegen®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2022
Drug
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2025
Drug
Other Name(s): Xgeva®; Wyost™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Oct 2024
Drug
Other Name(s): Jakavi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2025
Drug
Other Name(s): Stivarga®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2023
Drug
Other Name(s): Tafinlar®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2025
Drug
Other Name(s): Istodax®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2023
Drug
Other Name(s): Cyramza®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2023
Drug
Other Name(s): Darzalex®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daSATinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025

Pages